At the time of Abingworth’s investment in 2020, Vera was conducting mid-stage clinical trials of its lead product, atacicept, as a potential treatment for IgA Nephropathy (IgAN), the third most common cause of kidney disease. In July 2026, the FDA granted Vera accelerated approval for atacicept-vymj, brand name TRUTAKNA, to reduce proteinuria in adults with primary IgAN at risk for disease progression. TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgAN.